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ABSTRACT 
 
The purpose of this study was to examine the process of care in an interdisciplinary sleep clinic 
for patients with obstructive sleep apnea (OSA) and comorbid insomnia.  A mixed-methods 
approach was used to examine clinical and patient-centered measures for 34 patients who 
received positive-airway pressure and/or cognitive-behavior therapy for insomnia.  The results 
revealed baseline-to-follow-up improvements on several self-reported sleep parameters and 
measures of daytime functioning.  Qualitative analyses from patient interviews revealed three 
themes: conceptual distinctions about each sleep disorder, importance of treating both sleep 
disorders, and preferences with regards to the sequence of treatment.  These findings indicate 
that patients with OSA and comorbid insomnia encounter unique challenges and a dimensional 
approach to assessment and treatment is proposed for future research.   
 
Key Words:  obstructive sleep apnea, comorbid insomnia, cognitive-behavior therapy, positive 
airway pressure  
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INTRODUCTION 
Insomnia and obstructive sleep apnea (OSA) are two highly prevalent sleep disorders, 
with the co-occurrence of both insomnia and OSA symptoms ranging from 55% to 84% of 
patients presenting to sleep clinics (Krakow & Ulibarri, 2013; Krell & Kapur, 2005; Lichstein,   
Thomas, Woosley, & Geyer, 2013; Subramanian et al., 2011) and 20 to 40% when more 
stringent criteria consistent with an insomnia disorder are applied (Krakow, Ulibarri, Romero, & 
McIver, 2013; Smith, Sullivan, Hopkins, & Douglas, 2004).  While the etiological relationship 
between OSA and comorbid insomnia remains unclear, the presence of both OSA and insomnia 
presents challenges to traditional management approaches focusing on only one disorder.  For 
example, polysomnography is not routinely used for patients who complain of chronic insomnia 
and occult OSA might remain undetected (Krakow et al., 2001; Lichstein, Riedel, Lester, & 
Aguillard, 1999).   The comorbidity can also impact treatment effectiveness, as the presence of 
insomnia has been found to be a predictor of poor compliance with positive-airway pressure 
(PAP), the standard treatment for OSA (Bjornsdottir et al., 2013; Pieh et al., 2013; Wallace, 
Shafazand, Aloia, & Wohlgemuth, 2013; Wickwire, Smith, Birnbaum, & Collop, 2010).   
Responding to these challenges, multidisciplinary teams have emerged as a 
recommended approach to improve patient outcomes and cost-effectiveness in sleep clinics.  A 
multidisciplinary model that has been used for patients with comorbid OSA and insomnia is the 
combination of behavioral sleep medicine (BSM) with a standard sleep medicine clinic 
(Guilleminault, Davis, & Huynh, 2008; Krakow et al., 2004; Ong & Crisostomo, 2013).  Krakow 
and colleagues (2004), examined outcomes from a sequential multidisciplinary treatment 
approach using cognitive-behavior therapy for insomnia (CBTI) first, followed by OSA 
treatment, using PAP, oral appliance, or turbinectomy.  The findings revealed that outcomes on 
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insomnia severity and daytime functioning were optimized after patients received both CBTI and 
an OSA treatment relative to CBTI only. Using a prospective crossover design, Guilleminault 
and colleagues (2008) examined a combination of CBTI and a surgical intervention for those 
with mild OSA and insomnia, revealing that the optimal pathway for improving objective and 
subjective measures of sleep involved surgical intervention for OSA followed by CBTI.  
Although these studies provide preliminary evidence to support the use of CBTI in combination 
with an established OSA treatment, patient-centered issues related to education about treatment 
pathways and acceptability of a multidisciplinary approach have not yet been reported.   
The aim of this study was to examine the process of care from the patient perspective and 
to identify important issues related to the assessment and delivery of treatment within an 
interdisciplinary sleep clinic for patients with OSA and comorbid insomnia.  To carry out this 
aim, we used a mixed-methods approach to gather quantitative and qualitative data on both 
clinical and patient-centered measures.  This approach is useful in generating new hypotheses 
about clinical care by integrating clinical data with themes that are derived directly from the 
patient perspective (Wittink, Barg, & Gallo, 2006).  Given that the interest was focused on 
patient care rather than treatment outcomes, we used an observational design across a range of 
treatment pathways to optimize generalizability to routine practice in sleep clinics.   
METHODS 
Standard Clinical Procedures and Setting 
The Rush Sleep Disorders Center is accredited by the American Academy of Sleep 
Medicine (AASM) with an interdisciplinary team consisting of a sleep medicine clinic, staffed 
by physicians, and a BSM clinic, staffed by psychologists (described in Ong & Crisostomo, 
2013).  Figure 1 provides an overview of our treatment model.  Patients who presented for OSA 
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evaluation were seen by physicians in the sleep medicine clinic.  All patients were first seen for 
an initial clinic evaluation, which included a review of the patient’s presenting complaint, 
medical and psychiatric history, and a physical examination. Following this evaluation, patients 
with probable OSA received an in-lab overnight diagnostic polysomnography (PSG) study 
following established guidelines (Epstein et al., 2009).  Scoring was conducted by registered 
polysomnography technologists following the AASM Manual for Scoring Sleep (Iber, Ancoli-
Israel, Chesson, & Quan, 2007) and reviewed and interpreted by the sleep physicians. When 
OSA was diagnosed, patients received a PAP titration following standard protocol (Kushida et 
al., 2008) as part of a split-night study or on a second overnight study.  Once a successful PAP 
titration was completed and reviewed by the sleep physician, orders were sent to a Durable 
Medical Equipment vendor, who provided home set-up of the PAP machine, education regarding 
care and maintenance of the machine, and follow-up for mask-related issues and PAP 
compliance data.  Patients were asked to contact their sleep physician one week after the home 
set-up to verify initiation of PAP treatment and discuss any initial issues related to PAP use. 
Subsequently, patients were scheduled for a follow-up clinic visit approximately 90 days after 
initiation of PAP to evaluate treatment progress.  The in-lab studies and at-home PAP treatment 
were managed by board-certified physicians in sleep medicine according to standard care 
(Epstein et al., 2009; Kushida et al., 2006).  
Patients referred for insomnia evaluation or whose primary complaint was difficulty 
initiating or maintaining sleep were seen by psychologists in the BSM clinic.  First, an initial 
clinical evaluation was conducted to confirm the insomnia diagnosis and evaluate for other sleep 
disorders, if needed.  Following the initial clinic evaluation, patients who endorsed symptoms of 
insomnia received CBTI following published protocols (Perlis, Jungquist, Smith, & Posner, 
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2005) and practice guidelines (Morgenthaler et al., 2006), which includes stimulus control, sleep 
restriction, sleep hygiene education, and cognitive therapy.  CBTI was delivered individually by 
a psychologist Certified in BSM (CBSM) or by a psychology intern under the supervision of a 
CBSM psychologist. 
Cross-referrals between physicians and psychologists were driven by clinical presentation 
and clinician judgment within the context of routine clinical care without special instructions 
given to clinicians on when to make referrals.  If a patient who presented for OSA evaluation 
was suspected of having comorbid insomnia, the physician would refer the patient to the BSM 
clinic for CBTI.  Similarly, if a patient who presented with insomnia was suspected of having 
OSA, the psychologist would refer the patient to a sleep physician for further OSA evaluation 
and treatment.  Cross-referrals could be generated concurrently or sequentially depending on 
clinical judgment.     
Study Participants  
Potential research candidates were identified prospectively based upon symptoms 
reported during routine clinic visits (see procedures above) between December 2010 and October 
2012 (see Figure 2 for participant flow). Once a candidate was identified, a research staff 
member attempted to contact the candidate to conduct a brief screening interview (following the 
clinic visit or via telephone) and reviewed medical records (if needed) to assess study eligibility. 
The inclusion criteria for this study were: a) Age ≥ 18 years; b) ICSD-2 (American Academy of 
Sleep Medicine, 2005) criteria for OSA satisfied by at least one clinical symptom on the 
screening interview and later confirmed by AHI ≥ 5 on the diagnostic PSG; and c) ICSD-2 
(American Academy of Sleep Medicine, 2005)  and Research Diagnostic Criteria (Edinger et al., 
2004) for an insomnia disorder satisfied by a complaint of difficulty initiating or maintaining 
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sleep with significant daytime impairment or distress despite adequate opportunity and 
circumstance for sleep.  Patients were excluded if the initial clinic visit or diagnostic PSG was 
for suspicion of another sleep disorder (e.g., narcolepsy). This study was approved by the local 
Institutional Review Board and written informed consent was obtained by the research staff 
during the in-person screening interview or at the diagnostic PSG. 
Study Assessments and Procedures 
A baseline assessment was conducted on all participants shortly after enrollment, which 
consisted of questionnaires and one week of sleep/wake diaries along with data collected from 
routine medical care (i.e., physical exam and medical history).  Questionnaires were 
administered to gather clinical data, including the Insomnia Severity Index (ISI) (Morin, 
Belleville, Belanger, & Ivers, 2011), Pre-Sleep Arousal Scale (PSAS) (Nicassio, Mendlowitz, 
Fussell, & Petras, 1985), Beliefs and Attitudes about Sleep (BAS)  (Morin, 1993), Epworth 
Sleepiness Scale (ESS) (Johns, 1991), Fatigue Severity Scale (FSS) (Krupp, LaRocca, Muir-
Nash, & Steinberg, 1989), State-Trait Anxiety Inventory (STAI) (Spielberger, Gorsuch, & 
Lushene, 1970), and Beck Depression Inventory (BDI-II) (Beck, Ward, Mendelson, Mock, & 
Erbaugh, 1961).  Prospective sleep/wake diaries were used to assess self-reported sleep 
parameters along with ratings of sleep quality, daytime sleepiness, and daytime fatigue.   
Study patients were re-assessed at follow-up approximately 90 days after the baseline 
assessment or after they completed the treatment plan recommended by the sleep clinician. The 
90-day follow-up time frame was selected as it corresponds to current standards for evaluating 
progress with PAP treatment (Aloia, Knoepke, & Lee-Chiong, 2010) and allows sufficient time 
to complete 6 to 8 sessions of CBTI.  During the follow-up study visit, patients completed a 
questionnaire packet and one week of sleep diaries.  In addition to the questionnaires described 
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above, the experience and satisfaction of treatment was collected at follow-up using a 30-item 
Sleep Treatment Questionnaire (STQ) that was adapted from Parthasarathy and colleagues 
(Parthasarathy, Haynes, Budhiraja, Habib, & Quan, 2006).  The STQ consisted of one section 
pertaining to sleep apnea treatment, one section for insomnia treatment, and one section for 
overall treatment experience.  For qualitative data, a semi-structured interview was conducted as 
a focus group consisting of two to four patients, or as individual interviews when scheduling 
conflicts precluded participation in a focus group.  The structured interview consisted of general 
questions about the treatment experience (e.g., what did you like about your treatment plan?) 
along with specific questions about PAP and CBT (e.g., Do you feel this treatment made your 
insomnia/sleep apnea better?).  Interview questions were the same regardless of format (group or 
individual) and were designed to gather qualitative data on the evaluation and treatment process 
received by the patient.  Each interview was audio recorded using a handheld digital recording 
device (Olympus™ VN-8100PC) and subsequently transcribed verbatim and analyzed using 
thematic analysis.  
Data Analysis Plan 
A mixed methods approach was employed to integrate clinical data with patient-centered 
data for the purpose of exploring the contextual factors associated with interdisciplinary care.  To 
provide a context for interpreting the qualitative data, paired samples t-tests were conducted to 
examine baseline-to-follow-up changes across each clinical measure. To guard against inflated 
Type I error, significance was set at p<.01 and interpretation of the quantitative data was focused 
on clinical significance.  For qualitative data, thematic analysis was used as the method for 
coding and deriving themes from the patient interviews following guidelines established by 
Braun and Clarke (2006). Thematic analysis is a flexible technique used to analyze qualitative 
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data and is unrestricted by pre-existing theoretical frameworks (Braun & Clarke, 2006). Using an 
inductive approach, two trained raters (AK and MRC) independently coded each interview and 
then collated initial codes into overarching semantic themes. These themes were then refined in 
an iterative process, until consensus was reached between the two raters.  Themes of interest 
included those that pertained to the evaluation and treatment received as part of the 
interdisciplinary clinic and were distinct but not mutually exclusive.  Each theme along with 
verbal extracts is outlined below with the temporal location of the quote within the text and focus 
group summarized in Table 3.     
RESULTS 
A total of 423 patients were approached for participation in this study with 50 patients 
who provided written informed consent to enroll in this study.  After signing the consent, five 
patients received the diagnostic PSG and did not meet criteria for OSA (AHI < 5), three patients 
did not complete the diagnostic PSG study, and eight patients did not provide complete baseline 
data.  These 16 patients were excluded from the analyses, yielding a total of 34 patients for the 
final sample.  With regards to treatment sequence, 13 patients received PAP only, 3 received 
CBTI only, 16 received both PAP and CBTI, and 2 received other treatments outside of the Rush 
Sleep Disorders Clinic (see Figure 2).  Given that the primary aim of this paper was on the 
process of patient care rather than a comparison of treatment sequences, all analyses were 
collapsed across treatment sequences.  Participant characteristics and baseline medical status are 
summarized in Table 1.   
Clinical Measures  
Significant baseline-to-follow-up changes (p<.01) in the hypothesized direction were 
found on total wake time and sleep efficiency on the sleep diaries, PSAS total scores, ISI, and 
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FSS (see Table 2 for all p values and effect sizes). Using validated cut-off scores for clinical 
significance (Morin et al., 2011), 31.3% (10 out of 32 patients) no longer met criteria for 
insomnia (ISI ≥ 11) at follow-up with 12.5% (4 out of 32 patients) in remission (ISI < 8) and 
30.0% (9 out of 30 patients) meeting criteria for treatment response (ISI reduction > 7).  The 
percentage of patients who met the clinically significant cutoff for excessive daytime sleepiness 
(ESS > 10) decreased from 43.8% (14 out of 32) at baseline to 25.8% (8 out of 31) at follow-up.  
The percentage of patients who met the cutoff for excessive fatigue (FSS ≥ 36) decreased from 
81.3% (26 out of 32) at baseline to 68.8% (22 out of 32) at follow-up.  Using criteria (BDI ≥ 17) 
suggested for insomnia patients (Carney, Ulmer, Edinger, Krystal, & Knauss, 2009), the 
percentage of patients with depression symptoms decreased from 45.5% (15 out of 33) at 
baseline to 40.6% (13 out of 32 patients) at follow-up.  As seen in Table 2, effect sizes across 
clinical measures were generally above 0.20 (d > 0.20), indicating small to medium effect sizes 
from baseline to follow-up.  
Treatment Experience and Satisfaction 
Overall, 86.7% of patients (n=30) were either very satisfied (40%) or satisfied (46.7%) 
with the treatment they received for their sleep problems.  Ratings for OSA treatment (n=27) 
revealed that 48.1% were very satisfied and 44.4% were satisfied with their treatment.  
Furthermore, most patients endorsed adequate education (92.6%), understanding of OSA 
(88.9%), and understanding of OSA risks (85.2%).  Those who were prescribed PAP 
subjectively reported an average of 5.25 hours per night and 5.86 days per week.  Ratings for 
insomnia treatment (n=17) revealed that 43.8% were very satisfied and 37.5% were satisfied 
with their treatment.  Most patients reported adequate education of insomnia (82.4%), 
understanding of insomnia (76.4%), and understanding of the risks of insomnia (70.5%). Of the 
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19 patients who received CBTI, the average number of sessions was 3.32 (SD=2.11, range=1-8 
sessions). Patients who received CBTI reported using a behavioral strategy 4.64 days per week. 
The STQ also revealed quantitative data on the patients’ perception of their sleep 
problem.  When asked to identify their primary sleep problem (n=29), 24.1% reported OSA, 
24.1% insomnia, and 48.3% reported both.  For their first choice of treatment (n=25), 48% 
reported PAP, 20% reported sleep medication, and 8% reported CBTI while 29.6% reported 
weight loss as the second choice treatment (n=27).  With regards to daytime symptoms (n=30), 
30% reported substantial improvement in daytime symptoms and 43.5% reported slightly 
improved. With regards to nighttime symptoms (n=30), 30% reported substantial improvement 
and 33.3% reported slight improvement. No patient reported complete resolution of their daytime 
and nighttime symptoms.   
Patient Interviews  
Twenty-nine participants completed a follow-up interview either in individual or group 
format. Nineteen interviews were conducted over the course of this study and each was 
facilitated by one or two members of the research team. Three themes specific to this comorbid 
population were identified and are described below, with specific supporting comments from 
participants reported in Table 3.  
Theme 1: Conceptual distinctions between OSA and insomnia. The first theme involved 
patient’s knowledge and their conceptualization of sleep problems.  Patients described insomnia 
as a problem “fall[ing] asleep”, or one associated with reduced sleep quantity; whereas OSA 
was typically characterized as a problem “stay[ing] asleep”, associated with poor sleep quality 
(see table 3, quotes 1.1-1.5). The distinction was also evident when patients were asked to 
describe the predisposing and precipitating factors associated with their sleep problem. Patients 
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described symptoms either specific to insomnia (job stress, racing mind, family issues) or OSA 
(gender, weight, family history). Other patients referred to factors that were associated with both 
OSA and insomnia (e.g. genetics).  Even when patients were able to distinguish between the two 
sleep disorders, there was confusion as to why a single “sleep doctor” could not address their 
sleep disturbance as a whole (table 3, quote 1.6). 
Theme 2: “Co-morbidity” demands “co-treatment.”  With the distinction of these two 
conditions, patients almost unanimously agreed on the importance of treating both conditions 
“from a more holistic perspective” (table 3, quotes 2.1 and 2.2).  A number of patients reported 
insomnia symptoms that were left untreated by PAP, commenting on the difficulty adhering to 
PAP while lying awake in bed, and that PAP is actually not beneficial if they were not sleeping 
(table 3, quotes 2.3 and 2.4). According to one individual, residual insomnia actually “knocks 
off” the effectiveness of PAP (table 3, quote 2.5). There was a clear consensus that CBTI had 
little impact on their OSA symptoms.  In contrast, PAP alone was reported to have some positive 
impact on sleep maintenance but not substantially on sleep onset latency. Patients were 
“frustrated” trying to use PAP, stating residual difficulties with insomnia as the cause (table 3, 
quote 2.6). Individuals who experienced difficulties using PAP also discussed the negative 
impact that PAP had on untreated insomnia (table 3, quote 2.7 and 2.8). 
Theme 3: Patient preferences for treatment sequence.  Patients articulated unique 
contextual factors that dictated the sequence or order of the treatments.  The majority of patients 
expressed a preference to initiate PAP treatment first, followed by CBTI or another treatment for 
insomnia. Prioritising PAP was important as some questioned whether a patient would be 
medically stable enough to “forgo the machine” (table 3, quotes 3.1 and 3.2). Others who 
preferred concurrent treatment or preferred to initiate CBTI first, emphasized how untreated 
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insomnia could interfere with PAP use and felt that treating insomnia first would improve the 
effectiveness of PAP. Another contextual factor regarding treatment-decision of sequence was 
the general dislike and potential stigma associated with PAP treatment.  One individual was 
explicit about his stigma of using PAP, associating the treatment with being almost “dead”. 
CBTI on the other hand was not perceived with the same dislike or stigma.  Most participants 
who did not find insomnia symptoms to be alleviated by PAP were open to trying CBTI. Some 
patients who favored sequential treatment described completing both treatments simultaneously 
as “brutal”.  For example, adherence to the stimulus control component of CBTI was considered 
challenging while wearing a PAP mask (table 3, quote 3.3). These patients suggested adaptations 
to stimulus control, such as specific instructions on how to remove the mask if the need arises to 
get out of bed due to sleeplessness.  Concurrent treatment also obfuscated some patients’ ability 
to make attributions regarding the effectiveness of each treatment (table 3, quote 3.4). Finally, 
some patients expressed a preference for treatment planning that included consideration of the 
patient’s individual situation and the complexity of managing multiple medical conditions. 
DISCUSSION 
The present study is the first to examine the process of care from the patient perspective 
in an interdisciplinary sleep clinic featuring CBTI and PAP for patients with OSA and comorbid 
insomnia.  The findings revealed important contextual factors regarding the patient experience, 
which has not been previously reported for this comorbid population.  First, patient knowledge 
about sleep disorders and their consequences was an important factor to those who received 
treatment.  The majority of patients endorsed adequate education about both OSA and insomnia.  
Consistent with findings by Parthasarathy and colleagues (Parthasarathy et al., 2006; 
Parthasarathy, Subramanian, & Quan, 2014), patient education appears to be an important aspect 
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of high quality patient care in accredited sleep centers. However, education about the individual 
sleep disorders may not necessarily enable the individual to form accurate conceptualizations of 
the co-morbidity between insomnia and OSA, suggesting the need for more specific adaptations 
of patient education for this comorbid group.  Qualitative data from patient interviews revealed 
that patients’ distinction between OSA and insomnia involved sleep disturbance phenotypes 
(onset vs. maintenance) or the sleep quality/quantity dimension.  Specifically, insomnia was 
considered a problem occurring at sleep onset while OSA was considered a problem with sleep 
maintenance.   This distinction is interesting given that sleep onset insomnia has been shown to 
persist despite PAP treatment (Bjornsdottir et al., 2013).  Even when patients were able to 
distinguish between the two sleep disorders, there was confusion as to why a single “sleep 
doctor” could not address their sleep disturbance as a whole, even though they believed in 
treating both conditions.  Thus, better integration and more specific education about distinctions 
between the symptoms of OSA and insomnia could improve patient care.  
Second, important contextual factors related to the delivery of PAP and CBTI were 
revealed in this study.  Several patients reported difficulty and frustration of using PAP while 
lying awake in bed, indicating that untreated or residual insomnia reduced the effectiveness of 
PAP, an experience that is consistent with previous reports from the literature (Bjornsdottir et al., 
2013; Pieh et al., 2013; Wallace et al., 2013; Wickwire et al., 2010).  However, some patients 
reported that the use of PAP alone led to improvements in sleep maintenance but not for sleep 
onset.  One noteworthy challenge involves the difficulties of following the stimulus control 
instructions of getting out of bed while using PAP.  It might not be clear to patients whether it is 
more important to continue wearing the mask or to get out of bed and go to another room, as 
instructed.  Therefore, the delivery of CBTI and PAP in an interdisciplinary sleep clinic should 
OSA AND INSOMNIA   15 
 
 
consider adaptations or modifications of instructions that account for the interaction between the 
two sleep disorders and their treatments.  For example, clinicians should discuss a specific plan 
with patients regarding what to do with PAP machines as part of delivering stimulus control 
instructions, or consider implementing stimulus control after treatment with PAP is stabilized.   
Third, several specific considerations related to treatment decision-making were unveiled 
for this comorbid group.  The STQ revealed that 48% rated PAP as their first choice of treatment 
while only 8% endorsed CBTI as the first choice of treatment.  This was corroborated by patient 
interviews where most preferred PAP treatment for OSA as the first line treatment while CBTI 
was seen with less urgency as an adjunct or secondary treatment.  Interestingly, treatment 
preference was not directly related to patients’ primary concern, considering that 48.3% of 
patients reported both OSA and insomnia as the primary problem and 21.4% of patients reported 
either OSA or insomnia. Furthermore, these quantitative ratings in treatment preferences did not 
appear to reflect the negative perception of PAP treatment compared to CBTI that was reported 
in the patient interviews.  Thematic analysis of patient interviews also revealed that patients 
based treatment decisions on physician recommendations, perception of OSA severity, or feeling 
over-burdened by experiencing both treatments concurrently.  Several participants expressed 
greater satisfaction with their care when their treatment plan was individualized and took account 
of the complexities of having both OSA and insomnia.  This indicates that patients could benefit 
from shared decision-making that includes a discussion about the expectations of treatment, 
patient preferences, and the capacity for treatment. 
Overall, patients who were engaged in treatment reported positive clinical effects on 
nocturnal symptoms and daytime functioning that are similar to or slightly lower than those 
reported for CBTI (Irwin, Cole, & Nicassio, 2006; Morin, Culbert, & Schwartz, 1994; Smith et 
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al., 2002)  and PAP (Balk et al., 2011; Engleman, Martin, Deary, & Douglas, 1994).  Over 86% 
of patients expressed overall satisfaction with the treatment they received with high rates of 
satisfaction for each modality of treatment.  However, global measures from the STQ and 
clinical significance criteria revealed a more modest clinical profile.  No patient reported 
complete resolution of their sleep problems with 33.3% reporting no change in nighttime 
symptoms and 23.3% reporting no change in daytime symptoms.  At follow-up, only 12.5% of 
the patients were in remission for insomnia and only 30% met criteria for treatment response, 
with 68.8% of patients still reporting excessive fatigue. Notably, the mean number of CBTI 
sessions attended was only 3.32, which is suboptimal according to recommendations for CBTI 
delivery (Perlis et al., 2005) and might account for the low treatment response on insomnia 
outcomes.  Continued efforts are needed to achieve better outcomes across the full range of 
nighttime, daytime, and emotional issues that are prominent in this population. 
 Several limitations should be noted in this observational study.  First, treatments were 
delivered according to standard care using clinical judgment and not protocol-driven as would be 
done in a randomized controlled trial.  This led to variability in treatment plans, including the 
combination and sequence of treatments, as well as variability in clinic attendance and 
completeness of follow-up data.  There was also a potential for response bias, as those who were 
not satisfied with treatment or did not perceive benefits might not have returned to the clinic and 
provided follow-up data.  Therefore, the outcome and satisfaction data should be interpreted with 
caution.  Second, no control group was available so baseline-to-follow-up changes cannot be 
attributed specifically to the treatments provided.  Third, this was a relatively small sample size, 
which might not generalize to other sleep clinics.  Fourth, our sleep clinic does not routinely 
score respiratory event related arousals (RERAs), which could have an impact on diagnosis and 
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treatment in this population.  Finally, the limitations of thematic analysis should be 
acknowledged, including subjective interpretations of patient responses and the potential for 
investigator bias in identifying themes.  
Despite these limitations, the present findings serve as a starting point towards tailoring 
treatment delivery and optimizing clinical resources in sleep clinics for patients with OSA and 
comorbid insomnia.   Based on our findings that traditional diagnostic categories (i.e., OSA, 
insomnia) might create confusion for patients with multiple sleep disorders, one proposal would 
be to use a dimensional approach to assessing and treating patients who have comorbid sleep 
disorders.  Such an approach could use patient-reported ratings and clinical findings across 
symptoms (or functional domains) to generate a profile based on the degree to which each 
symptom (or area of dysfunction) is present.  This profile, similar to Bussye’s (2014) 
dimensional profile of sleep health, could then be used to develop a personalized treatment plan 
matching the most urgent or intense symptoms as perceived by patients with tailored treatment 
components (e.g., sophisticated PAP devices better suited for patients with comorbid insomnia, 
stimulus control modified for PAP use).  Furthermore, patients can be introduced to a team-based 
approach with providers (i.e., physicians, psychologists, nurses) who have relevant expertise in 
delivering these tailored treatments, which can encourage shared decision-making based on 
treatment preferences and concerns.  This dimensional and team-based approach could serve as 
an innovative model for interdisciplinary sleep clinics and an area for future research. 
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Table 1. Baseline Patient Characteristics. 
 
Age, mean (SD) 54.11 years (13.27)  
Gender, % 61.8% female, 38.2% male 
Ethnicity, %  94.1% Non-Hispanic, 5.9% Hispanic 
Race, % 47.1% White, 47.1% Black, 5.9% Asian 
Relationship Status, % 44.1% married/engaged, 35.3% single, 20.6% 
divorced/separated/widowed 
Education, mean (SD) 15.46 years (3.79) 
Comorbid medical conditions, mean (SD) 7.0 (4.5) 
   HEENT, % ≥ 1 condition 
   CV, % ≥ 1 condition 
   Respiratory, % ≥ 1 condition 
   GI, % ≥ 1 condition 
   GU, % ≥ 1 condition 
   Musculoskeletal, % ≥ 1 condition 
   Endocrine, % ≥ 1 condition 
   Hematological, % ≥ 1 condition 
   Psychiatric, % ≥ 1 condition 
   Neurological, % ≥ 1 condition 
38.3% 
64.7% 
38.2% 
55.9% 
20.6% 
70.6% 
61.8% 
29.4% 
64.7% 
20.6% 
  Rheumatologic, % ≥ 1 condition 8.8% 
Number of medications, mean (SD) 8.2 (5.1) 
Number of sedating/alerting medications, 
mean (SD) 
2.1 (1.6) 
BMI, mean (SD) 37.59 (10.93) 
AHI, mean (SD) 31.57 (35.26) 
OSA Severity Mild (n=13), Moderate (n=12), Severe (n=9)  
PAP pressure, mean (SD)  12.40 cm H2O (5.86) 
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Note. Medical conditions were reviewed by the sleep physicians (MP, MIC, EA) and categorized 
based on reported past medical history or inferred from medication use and medications were 
reviewed and categorized according to medical indication. Each category under comorbid 
medical conditions represents the percentage of patients with at least one comorbid condition in 
that category.  HEENT = Head, Eyes, Ears, Nose, Throat, CV = cardiovascular, GI = 
gastrointestinal, GU = genitourinary, BMI=Body Mass Index, AHI = Apnea-Hypopnea Index, 
PAP = positive airway pressure. For OSA severity, mild = AHI ≥ 5 but < 15, moderate = AHI ≥ 
15 but < 30, severe = AHI ≥ 30.  
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Table 2. Baseline to Follow-up Data 
 
Measures Baseline  Follow-up      
 M SD M SD df t p d 
Sleep Diary Data         
SOL (min) 56.26 66.66 32.45 25.71 28 -2.09 .046 -.35 
 WASO (min) 57.43 53.83 42.70 45.02 27 -2.72 .081 -.42 
 TWT (min) 115.30 79.12 74.56 51.78 27 -3.30 .003 -.53 
TST (min) 395.35 109.96 417.04 118.51 27 1.72 .097 .24 
TIB (min) 505.35 89.75 493.06 104.17 28 -0.73 .474 -.15 
SE (%) 77.85 13.23 84.45 11.43 27 3.20 .003 .52 
NWAK 2.39 1.07 2.17 1.16 28 -1.81 .081 -.20 
Daytime Alertness 44.61 20.50 53.77 20.88 29 2.09 .046 .34 
Pre-Sleep Arousal Scale (Total) 42.12 12.27 36.19 10.57 30 -2.90 .007 -.46 
 Cognitive  23.45 6.67 20.50 7.07 30 -2.69 .012 -.39 
 Somatic  18.67 7.02 15.69 5.32 30 -2.82 .008 -.49 
Insomnia Severity Index 17.94 5.47 14.50 5.78 29 -3.42 .002 -.55 
Beliefs and Attitudes about Sleep 134.79 44.42 124.34 41.63 31 -1.60 .120 -.27 
State-Trait Anxiety Inventory 47.71 13.67 44.58 13.14 31 -2.42 .021 -.37 
Beck Depression Inventory 17.58 11.22 16.50 13.27 30 -0.71 .484 -.13 
Epworth Sleepiness Scale  9.97 5.62 8.10 5.08 29 -2.61 .014 -.45 
Fatigue Severity Scale  45.75 10.87 40.94 12.46 29 -3.35 .002 -.61 
 
Note.  SOL = sleep onset latency; WASO = wake after sleep onset; TWT = total wake time, TST 
= total sleep time; TIB = time in bed; SE = sleep efficiency; NWAK = Number of Awakenings. 
Daytime alertness is rated from 0 (very sleepy) to 100 (very alert), with lower numbers reflecting 
greater levels of sleepiness and higher numbers rating greater levels of alertness. 
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Table 3. Patient Interview Themes and Responses 
Theme Verbal extract Patient Details Interview/Focus Group Details 
1. Conceptual 
distinctions 
between OSA and 
insomnia 
1.1“with insomnia you are going to want to fall 
asleep. But also with using sleep apnea [CPAP], 
you want to try to find a way to stay asleep.”  
Male, 42 yr,  
Treatment: PAP + CBTI 
  
 
Interview 1, lines 478-480, 
participant ID 0002 
1.2“My sense is that they are not very much 
related, you know that the awaking from the 
episodes of apnea were that, they were not part of 
the insomnia, the bad sleep habits or whatever.”  
  
 
Male, 68 yr,  
Treatment: PAP → CBTI 
Interview 8, lines 153-155, ID 0023 
1.3“I didn’t know if they [physicians] knew that I 
had insomnia, I didn’t know if I [emphasis] knew 
I had insomnia [...] I knew I wasn’t sleeping. But 
I had related it to be sleep apnea, not insomnia.” 
  
 
Male, 63 yr,  
Treatment: PAP → CBTI 
Interview 5, lines 186-188, ID 0017 
1.4 “I’m never conscious like ‘now I have sleep 
apnea’, no, I sleep through sleep apnea or I wake 
up and not knowing it was caused by sleep apnea. 
So [...] there is probably less interruptions than 
there was before [insomnia treatment]. So I pose 
that is evidence that [insomnia treatment] is 
working.”  
  
 
Male, 56 yr,  
Treatment: PAP + CBTI 
Interview 2, lines 381-384, ID 0001 
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1.5“They weren’t treating me for both. We are 
finding out that I need (stress) treatment for both. 
Ah when I first came, it was just for the apnea. 
Now we are leaning more towards the insomnia.”  
Female, 52 yr,  
Treatment: PAP → CBTI 
  
 
Interview 14, lines 9-11, ID 0045 
1.6 “why are there two different[sleep doctors] I 
understand why there is (sic) two different 
disciplines [...]it seemed to me that having a 
sleep doctor...would understand both sides of the 
equation.”  
Male, 46 yr,  
Treatment: PAP only 
Interview 1, lines 485-488, ID 0004 
2. “Co-morbidity” 
demands “co-
treatment” 
2.1 “I think that you should approach [treatment] 
from a more holistic perspective, rather than 
siding each individual discipline. Because 
overall, you are treating the patient, right; and so 
you know, this person has this set of problems.” 
Male, 46 yr,  
Treatment: PAP only 
Interview 1, lines 488-490, ID 0004 
2.2 “I would say try [the treatments] both at the 
same time. Because one has to get to complement 
the other one.”  
Male, 68 yr,  
Treatment: PAP → CBTI 
Interview 8, lines 686-687, ID 0023 
2.3 “I believe its [CPAP] function is to make sure 
that I am breathing while I am sleeping. Well it’s 
not about breathing while I’m sleeping at this 
point. It’s about getting to sleep and staying 
asleep.”  
Female, 52 yr,  
Treatment: PAP → CBTI  
Interview 14, lines 120-122, ID 0045 
2.4 “I needed most help, I think, with insomnia. 
Is [...], if you’re not falling asleep, the CPAP is 
not going to do anything for you. From my 
understanding anyway, it doesn’t really help you 
when you are awake.”  
Male, 56 yr,  
Treatment: PAP + CBTI 
Interview 2, lines 477-479, ID 0001 
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2.5 “the machine is very helpful, but with the 
insomnia, it just kind of knocks it off.”  
Female, 39 yr,  
Treatment: CBTI → PAP  
Interview 12, lines 153, ID 0040 
2.6 “I didn't see any results, and I think it was the 
insomnia that made me more frustrated with the 
CPAP machine.”  
Male, 56 yr,  
Treatment: PAP + CBTI  
Interview 2, lines 277-279, ID 0001 
2.7 “Now with the CPAP machine, when I do 
[emphasis] go sleep, it has helped me with you 
know like restful sleep. But since I do have the 
insomnia, the thing is I’ve got to train myself to 
do go to bed, to use the CPAP.”  
Female, 67 yr,  
Treatment: PAP + CBTI 
Interview 4, lines 141-143, ID 0014 
2.8 “I think it might be a little worse [...]. I wake 
up in the middle of the night. I don’t know if I’m 
waking up because of the air is (sic) blowing in 
my eyes, or if I’m waking up by myself and I am 
noticing that I have air blowing in my eyes.”  
Female, 37 yr,  
Treatment: PAP only 
Interview 10, lines 68-74, ID 0027 
3. Patient 
preferences for 
treatment sequence 
3.1 “I was just wondering if the decision the 
physician would have to make, if the person is 
physically healthy enough for (sic) forgo the 
machine.”  
Male, 56 yr,  
Treatment: PAP + CBTI 
  
Interview 2, lines 627-628, ID 0001 
3.2 “If [the sleep apnea] is mild , then do 
insomnia [treatment] first. Because the insomnia 
is teaching you how to go to sleep. And with sleep 
apnea, it’s like staying asleep and kind of 
breathing and continue breathing.”  
Male, 42 yr, 
Treatment: PAP + CBTI  
Interview 1, lines 398-400, ID 0002 
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3.3 “it would have been better to try to treat the 
insomnia first, and then introduce the CPAP 
sometime later [...] but getting out of bed because 
I’m not asleep yet, in that situation [concurrent 
treatment], was brutal.”  
Male, 56 yr,  
Treatment: PAP + CBTI 
Interview 2, lines 86-89, ID 0001 
3.4 “I doubt [that insomnia treatment had any 
influences on sleep apnea], but I don’t know how 
to separate that out since I never sleep without 
the CPAP.”  
Male, 67 yr, 
Treatment: PAP → CBTI 
Interview 13, lines 199-200, ID 0043 
 
Note: The quotes presented in this table were selected as representative data for each theme.  Matching each quote, we present 
information about the patient’s gender, age, treatment (and order) received, the interview number, lines in the transcription the quote is 
selected from, and the participant identification (ID) number. For treatment received, PAP + CBTI = received both PAP and CBTI 
concurrently; PAP → CBTI = received PAP first, followed by CBTI second; CBTI → PAP = received CBTI first, followed by PAP 
second. 
 
